Usted buscó: metabolizuojanci (Lituano - Inglés)

metabolizuojanci ferment induktoriai.
inducers of metabolic enzymes:

todl vaistus metabolizuojanci ferment indukcijos atmesti negalima.
the induction of metabolizing enzymes cannot therefore be excluded.

kartu su medikamentus metabolizuojanci ferment inhibitoriais reikia vartoti maziausi veiksming paroksetino doz.
when paroxetine is to be co-administered with a known drug metabolising enzyme inhibitor, consideration should be given to using paroxetine doses at the lower end of the range.

blogiau metabolizuojanci suaugusi ir vaik, gydom pagal amzi paskaiciuota doze, ekspozicija buvo ta pati.
exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses.

tiktina, kad tok ekspozicijos padidjim dalinai galima paaiskinti jaun ziurki vaist metabolizuojanci ferment nebrandumu.
the increased exposure was likely at least partly due to immaturity of the drug-metabolising enzymes in juvenile animals.

kit stipri vaistinius preparatus metabolizuojanci ferment induktori, toki kaip fenitoinas ar fenobarbitalis, poveikis ugt1a1 yra nezinomas.
the impact of other strong inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on ugt1a1 is unknown.

taigi pm asmen lansoprazolo ekspozicija yra kelis kartus didesn uz gerai metabolizuojanci (em) asmen.
the exposure of lansoprazole is several-fold higher in pms than in extensive metabolisers (ems) .

vaistinius preparatus metabolizuojantys fermentai paroksetino metabolizmas ir farmakokinetika gali kisti ir indukavus, ir uzslopinus vaistinius preparatus metabolizuojanci kepen ferment aktyvum.
drug metabolising enzymes the metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug metabolising enzymes.

kai kartu vartojama metabolizuojanci ferment induktori, reikia pagalvoti apie cancidas dozs padidinim iki 70 mg po 70 mg pradins dozs (zr.
when co-administering inducers of metabolic enzymes, an increase in the daily dose of cancidas to 70 mg, following the 70 mg loading dose, should be considered.

si tyrim metu paaiskjo, kad abakaviras didina vidutin metadono bendrj klirens 22%, todl vaistus metabolizuojanci ferment indukcijos atmesti negalima.
in this study, abacavir increased the mean methadone systemic clearance by 22%.the induction of drug metabolizing enzymes cannot therefore be excluded.

atliekant ikiklinikinius tyrimus in vitro ir in vivo ambrisentanas kliniskai reiksmingomis koncentracijomis neslopino ir nesuzadino i ar ii fazs vaist metabolizuojanci ferment, o tai rodo, kad ambrisentanas mazai gali pakeisti siuo bdu metabolizuojam vaist metabolin proces.
ambrisentan does not inhibit or induce phase i or ii drug metabolizing enzymes at clinically relevant concentrations in in vitro and in vivo non-clinical studies, suggesting a low potential for ambrisentan to alter the profile of medicinal products metabolized by these pathways.

kai kartu vartojama metabolizuojanci ferment induktori, reikia pagalvoti apie cancidas dozs padidinim iki 70 mg po 70 mg pradins dozs (zr.4. 2 skyri) .
when co-administering inducers of metabolic enzymes an increase in the daily dose of cancidas to 70 mg, following the 70 mg loading dose, should be considered (see section 4.2) .

kartu vartojant jonazols (hypericum perforatum) preparatus, dl pastarosios sukeliamos metabolizuojanci ferment ir/arba pernesanci baltym indukcijos gali sumazti nelfinaviro koncentracija plazmoje.
plasma levels of nelfinavir can be reduced by concomitant use of the herbal preparation st.john 's wort (hypericum perforatum) .this is due to induction of drug metabolising enzymes and/or transport proteins by st.john 's wort.

tyrimais in vitro nustatyta, kad atozibanas nra metabolizuojamas citochromo p450 sistemoje, jis taip pat neslopina vaistus metabolizuojanci p450 sistemos ferment.todl atozibano sveika su vaistais, kuriuos metabolizuoja citochromo p450 sistema, mazai tiktina.
it is unlikely that atosiban is involved in cytochrome p450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome p450 system, and does not inhibit the drug metabolising cytochrome p450 enzymes.

sio blogai metabolizuojancio fenotipo daznis panasus tarp suagusij (6%) ir vaik nuo 2 iki 11 met amziaus (6%) , taciau daznesnis tarp juodaodzi (18% suagusij ir 16% vaik) nei tarp baltj (2% suagusij ir 3% vaik) abiejose amziaus grupse.
the prevalence of this poor metaboliser phenotype was comparable for adult (6%) and paediatric subjects 2-to 11-year old (6%) , and greater among blacks (18% adult, 16% paediatric) than caucasians (2% adult, 3% paediatric) in both populations.